Cargando…

COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis

BACKGROUND: COVID-19 is an international outbreak of the respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The diseases themselves, as well as the intensity of chemotherapy, lead to significant immunosuppression, leading hematological malignancy patients sus...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Can, Weng, Qianping, Li, Yiwei, Shi, Pengfei, Qian, Shenxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458179/
https://www.ncbi.nlm.nih.gov/pubmed/32871864
http://dx.doi.org/10.1097/MD.0000000000021376
_version_ 1783576140741345280
author Chen, Can
Weng, Qianping
Li, Yiwei
Shi, Pengfei
Qian, Shenxian
author_facet Chen, Can
Weng, Qianping
Li, Yiwei
Shi, Pengfei
Qian, Shenxian
author_sort Chen, Can
collection PubMed
description BACKGROUND: COVID-19 is an international outbreak of the respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The diseases themselves, as well as the intensity of chemotherapy, lead to significant immunosuppression, leading hematological malignancy patients susceptible to infections. METHODS: This protocol will be performed according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and reported follow the Cochrane Collaboration Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic databases of PubMed, MEDLINE, Google Scholar, Web of science, Cochrane Library, EMBASE, CNKI, CMB, and Wangfang database from the inception to present will be comprehensively and systematically searched without limitations of language, date, and publication status. Observational, retrospective cohort, prospective case-control, cohort studies, cross-sectional studies, or clinical trials will be included. All assessment of study selection, data extraction, and study quality assessment will be independently performed by 2 reviewers. RevMan V.5.3 program and Stata V.12.0 software will be utilized for the methodological quality assessment and statistical analysis. RESULTS: The result of this systematic review will provide evidence for clinicians on the management of COVID-19 patients with hematological malignancy. CONCLUSION: This systematic review will help raise awareness and guide management of COVID-19 patients with hematological malignancy, as well as to improve outcomes in this population. ETHIC AND DISSEMINATION: The content of this article does not involve moral approval or ethical review because no individual data will be collected. PROSPERO REGISTRATION: CRD42020187493.
format Online
Article
Text
id pubmed-7458179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74581792020-09-11 COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis Chen, Can Weng, Qianping Li, Yiwei Shi, Pengfei Qian, Shenxian Medicine (Baltimore) 4900 BACKGROUND: COVID-19 is an international outbreak of the respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The diseases themselves, as well as the intensity of chemotherapy, lead to significant immunosuppression, leading hematological malignancy patients susceptible to infections. METHODS: This protocol will be performed according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and reported follow the Cochrane Collaboration Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic databases of PubMed, MEDLINE, Google Scholar, Web of science, Cochrane Library, EMBASE, CNKI, CMB, and Wangfang database from the inception to present will be comprehensively and systematically searched without limitations of language, date, and publication status. Observational, retrospective cohort, prospective case-control, cohort studies, cross-sectional studies, or clinical trials will be included. All assessment of study selection, data extraction, and study quality assessment will be independently performed by 2 reviewers. RevMan V.5.3 program and Stata V.12.0 software will be utilized for the methodological quality assessment and statistical analysis. RESULTS: The result of this systematic review will provide evidence for clinicians on the management of COVID-19 patients with hematological malignancy. CONCLUSION: This systematic review will help raise awareness and guide management of COVID-19 patients with hematological malignancy, as well as to improve outcomes in this population. ETHIC AND DISSEMINATION: The content of this article does not involve moral approval or ethical review because no individual data will be collected. PROSPERO REGISTRATION: CRD42020187493. Lippincott Williams & Wilkins 2020-08-28 /pmc/articles/PMC7458179/ /pubmed/32871864 http://dx.doi.org/10.1097/MD.0000000000021376 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle 4900
Chen, Can
Weng, Qianping
Li, Yiwei
Shi, Pengfei
Qian, Shenxian
COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title_full COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title_fullStr COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title_full_unstemmed COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title_short COVID-19 in hematological malignancy patients: A protocol for a systematic review and meta-analysis
title_sort covid-19 in hematological malignancy patients: a protocol for a systematic review and meta-analysis
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458179/
https://www.ncbi.nlm.nih.gov/pubmed/32871864
http://dx.doi.org/10.1097/MD.0000000000021376
work_keys_str_mv AT chencan covid19inhematologicalmalignancypatientsaprotocolforasystematicreviewandmetaanalysis
AT wengqianping covid19inhematologicalmalignancypatientsaprotocolforasystematicreviewandmetaanalysis
AT liyiwei covid19inhematologicalmalignancypatientsaprotocolforasystematicreviewandmetaanalysis
AT shipengfei covid19inhematologicalmalignancypatientsaprotocolforasystematicreviewandmetaanalysis
AT qianshenxian covid19inhematologicalmalignancypatientsaprotocolforasystematicreviewandmetaanalysis